From 1987-2000 HCB was Executive VP of the Women’s Health R&D programme at Organon in The Netherlands, where he was responsible for the development of RM drugs such as recFSH (Puregon) and the GnRH antagonist Antagon, both for IVF; the contraceptive vaginal ring (Nuvaring), a progestogen implant for contraception (Implanon), a progestogen-only desogestrel oral contraceptive (Cerazette) and the steroid tibolone (Livial) for menopausal hormone therapy (MHT).
HCB founded Pantarhei Bioscience in 2000, where he developed the natural fetal estrogen Estetrol (E4) for oral contraception and MHT, licensed out to Mithra Pharmaceuticals in Belgium in 2015, a new combined contraceptive pill containing DHEA to prevent the loss of testosterone (the ARC (Androgen Restored Contraception) pill), licensed out to Gedeon Richter in Hungary in 2018 and an immunological method for the treatment of Zona Pellucida 3 (ZP3) antigen expressing ovarian, prostate and lung cancer. The ovarian cancer ZP3 immunotherapy was licensed out to HRA in France in 2014. That same year Pantarhei Oncology was founded as a subsidiary of Pantarhei Bioscience to develop new cancer drugs in the field of Reproductive Endocrine Oncology (REO), with focus on improved endocrine treatment of advanced breast cancer (BC) and prostate cancer (PC). For both cancer applications successful phase 2 proof-of-concept studies have been completed and published in November 2020 (BC) and May 2021 (PC).